Steven Kao

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.4K citations · Full text

Haemolysis during Sample Preparation Alters microRNA Content of Plasma

Michaela B. Kirschner, Steven Kao, J. James Edelman et al. · PLoS ONE · 2011 · 512 citations · Full text

Vascular Disease, Engineering, Immunology +21

<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Alice T. Shaw, Benjamin Solomon, Benjamin Besse et al. · Journal of Clinical Oncology · 2019 · 371 citations · Full text

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy

Steven Kao, Nick Pavlakis, Rozelle Harvie et al. · Clinical Cancer Research · 2010 · 315 citations · Full text

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

Wendy A. Cooper, Trần Nam Thắng, Ricardo E. Vilain et al. · Lung Cancer · 2015 · 301 citations

Pd-l1 Expression, Favorable Prognostic Factor, Medicine +7